Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viatris Inc (NQ: VTRS )

9.860 +0.050 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,367,247
Open 9.840
Bid (Size) 9.850 (6)
Ask (Size) 9.990 (1)
Prev. Close 9.810
Today's Range 9.840 - 10.03
52wk Range 8.460 - 12.40
Shares Outstanding 1,212,301,241
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Could Viatris Stock Help You Become a Millionaire?
Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment? 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga

Performance

YTD
-13.36%
-13.36%
1 Month
-8.28%
-8.28%
3 Month
-0.30%
-0.30%
6 Month
+2.60%
+2.60%
1 Year
+15.73%
+15.73%

More News

Read More
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Via Benzinga
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
Via SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
Via Benzinga
Viatris Stock: Bear vs. Bull
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Via The Motley Fool
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Where Will Viatris Be in 5 Years?
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy
Via The Motley Fool
Is Viatris Stock Good for Dividend Income?
Via The Motley Fool
A Preview Of Viatris's Earnings
Via Benzinga
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Via Benzinga
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
Via Benzinga
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Via The Motley Fool
Viatris Stock: Bull vs. Bear
Via The Motley Fool
Daily Stock Analysis: Viatris
Via Talk Markets
Better Pharma Buy: Viatris vs. Pfizer
Via The Motley Fool
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
Via The Motley Fool
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.